-
You must submit the settlement Proof form attached below, in order to participate in this settlement. There is a strict deadline of November 16, 2020 by which all claims must be submitted. The instructions for submitting are included in the Proof and the Notice files attached below for your download. DO NOT SEND THE FORMS TO THE SHAREHOLDERS FOUNDATION, INC.
-
To have your information reviewed for options and to receive notifications about this case, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Lawsuit Overview
Settlement Overview
You must register to view and download the Settlement Notice and Settlement Proof.
December 16, 2020 - The court granted final approval of the settlement and final judgment.
August 18, 2020 - The court preliminarily approved the settlement.
August 17, 2020 - A stipulation and agreement of settlement was entered by the parties.
June 25, 2019 - An amended complaint was filed.
September 20, 2018 - An investor in shares of Cocrystal Pharma, Inc. (NASDAQ: COCP) filed a lawsuit in the U.S. District Court for the District of New Jersey over alleged violations of Federal Securities Laws by Cocrystal Pharma, Inc. in connection with certain allegedly false and misleading statements made between September 23, 2013 through September 7, 2018.
Cocrystal Pharma, Inc, formerly BioZone Pharmaceuticals, Inc,is a clinical stage biotechnology company that engages in discovering and developing various novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses.
On September 7, 2018, the U.S. Securities and Exchange Commission (“SEC”) filed a lawsuit against former officers of BioZone Pharmaceuticals, Inc as well as other individuals and corporations, alleging violations of the federal securities laws. The SEC complaint alleges that defendants were participants in “highly profitable ‘pump-and-dump’ schemes . . . from 2013 through 2018” in the stock of three public companies, including BioZone, that, “while enriching Defendants by millions of dollars, left retail investors holding virtually worthless shares.” According to the complaint the plaintiff alleges on behalf of purchasers of Cocrystal Pharma, Inc. (NASDAQ: COCP) common shares between September 23, 2013 through September 7, 2018, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between September 23, 2013 through September 7, 2018, the defendants made false and/or misleading statements and/or failed to disclose that the defendants were engaged in a pump-and-dump scheme to artificially inflate Cocrystal’s stock price, that this illicit scheme would result in governmental scrutiny, including from the SEC, that defendants failed to abide by SEC disclosure regulations, and that as a result, defendants’ statements about Cocrystal’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.